JAZZNasdaqPharmaceutical PreparationsUS GAAP · USD

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology. It commercializes products such as Xywav, Epidiolex/Epidyolex, Zepzelca, Rylaze, Vyxeos, Defitelio, Ziihera and Modeyso, while also advancing a pipeline of product candidates and pursuing acquisitions and in-licensing to expand its portfolio.

Ask about the company
Revenue4,268m USD
+4.9 %y/y
Operating profit (EBIT)-430m USD
−160.0 %y/y
EBIT margin-10.1%
−27.7 ppy/y
Net income-356m USD
−163.6 %y/y
Free cash flow1,297m USD
−4.5 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-1,00001,0002,0003,0004,0005,000m USD2020: 2,364 m USD2020: EBIT 378 m USD20202021: 3,094 m USD2021: EBIT 170 m USD20212022: 3,659 m USD2022: EBIT -66 m USD20222023: 3,834 m USD2023: EBIT 579 m USD20232024: 4,069 m USD2024: EBIT 717 m USD20242025: 4,268 m USD2025: EBIT -430 m USD20254,268-430
RevenueOperating profit (EBIT)
Ask Clarifo about Jazz Pharmaceuticals plc

Business

Share of revenue
Neuroscience medicines68 %

Commercial products for sleep disorders and epilepsy, including oxybate therapies and cannabidiol-based treatment.

Oncology medicines26 %

Hospital and specialty oncology products used in hematology and solid tumor settings.

Royalties and contract revenues6 %

Royalty income and other contract-based revenues tied to partnered or licensed assets.

Products

Reported · share of revenue
36.2%23.9%10.1%16.1%FY2024100 %
  • Xywav36.2 %
  • Epidiolex Epidyolex23.9 %
  • Rylaze Enrylaze10.1 %
  • Zepzelca7.9 %
  • Xyrem5.7 %
  • Other16.1 %

Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Jazz sells primarily to specialty pharmacies, specialty distributors, wholesalers, hospitals and institutional customers, with some products shipped directly to patients through certified pharmacies. Its customer base is concentrated in specialty care settings such as neurology, sleep medicine, hematology and oncology, where access, reimbursement and patient support are critical to adoption. In Europe, Canada and Australia, it also works through wholesalers, distributors and local medical affairs teams depending on market authorization and local regulation.

Specialty pharmacies

Buy Xywav, Xyrem, Epidiolex and Modeyso for controlled dispensing and direct patient shipment.

Hospitals and oncology institutions

Buy Defitelio, Vyxeos, Zepzelca, Rylaze and Ziihera for inpatient and outpatient cancer care.

Wholesalers and specialty distributors

Purchase and distribute products across the U.S. and international markets to maintain access.

Patients via certified channels

End users of oxybate and epilepsy therapies, reached through specialty pharmacy and reimbursement support.

International healthcare systems

Buy through local distributors, named-patient programs and market authorization pathways in Europe and Canada.

Strategy

Jazz is prioritizing commercial execution in neuroscience and oncology while expanding its pipeline through internal R&D, clinical trials and external product acquisition or in-licensing. Management also emphasizes disciplined capital deployment, including strategic transactions and selective financing, to build a broader portfolio of durable, differentiated assets. The strategy is designed to reduce dependence on any single product franchise and support long-term growth through launches, lifecycle management and portfolio expansion.

Commercialize and expand current marketed productsShort term

Existing products fund the business and support near-term growth while the company builds its pipeline.

Advance R&D and clinical developmentMedium term

Pipeline success is needed to replace mature assets and create longer-duration growth drivers.

Acquire or in-license differentiated assetsMedium term

External deal-making is a core path to portfolio expansion and diversification.

Geography

Q1/2026

Jazz operates directly in the U.S., Europe, Australia and Canada, and uses distributors in other key global markets. The U.S. is the core commercial market, while Europe and Canada are important for Defitelio, Vyxeos and Epidyolex/Epidiolex, and Australia is part of the direct commercialization footprint. The company also has a large international workforce, with about 47% of employees outside the U.S., mainly in the U.K., Ireland and the EU.

United States90 %
Europe8.6 %
Other countries (US filing)1.6 %

Share of the revenue the company reports by geography.

Risks

Jazz is exposed to concentration risk in its oxybate franchise and to execution risk around launching and scaling newer oncology products. Because its business depends on specialty channels, reimbursement, regulatory approvals and controlled distribution, pricing, access and compliance issues can materially affect demand and margins. The company also faces typical biopharma risks from clinical failure, patent and competition pressure, cybersecurity incidents and integration risk from acquisitions.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Loss of oxybate franchise revenue1Government investigations and drug pricing scrutiny2Clinical development and regulatory approval failure3Cybersecurity and IT incidents4Acquisition and integration risk5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Loss of oxybate franchise revenueImpact: HighLikelihood: High

    The company states that inability to maintain oxybate revenues would materially hurt business and growth prospects.

    Exposure: Xywav and Xyrem

  2. Government investigations and drug pricing scrutinyImpact: HighLikelihood: Medium

    Oversight can create legal expense, reputational damage and reduced market acceptance.

    Exposure: U.S. pricing and compliance practices

  3. Clinical development and regulatory approval failureImpact: HighLikelihood: Medium

    Pipeline value depends on successful trials and timely approvals for new products.

    Exposure: Oncology and neuroscience candidates

  4. Cybersecurity and IT incidentsImpact: MediumLikelihood: Low

    A breach or outage could interrupt operations, expose data and weaken internal controls.

    Exposure: Global commercial and R&D systems

  5. Acquisition and integration riskImpact: MediumLikelihood: Low

    Deal-making is central to strategy, but integration issues can impair returns and liquidity.

    ExposureProduct acquisitions and in-licensingIncluding Chimerix
Ask Clarifo about Jazz Pharmaceuticals plc

Accounting

Judgemental items
Revenue deductions and reserves

Gross sales are reduced by estimated rebates, chargebacks, returns and patient support, affecting reported net revenue.

Impact: Can materially change quarterly product sales and margins

Point-in-time revenue recognition

Product sales are recognized on transfer of control, including consignment-related timing.

Impact: Can shift revenue between periods based on shipment and patient dispensing timing

Goodwill impairment

The company reported $1.8 billion of goodwill and tests it annually for impairment.

Impact: A write-down would reduce earnings and signal weaker acquisition value

Acquisition-related contingent consideration and royalties

Recent acquisitions added milestone payments and royalty obligations.

Impact: Affects liabilities, future cash outflows and earnings presentation

Similar listed companies

Publicly listed companies with a comparable business focus.

Ionis Pharmaceuticals, Inc

IONS · Pharmaceutical Preparations

Vertex Pharmaceuticals Incorporated

VRTX · Pharmaceutical Preparations

Xenon Pharmaceuticals Inc.

XENE · Pharmaceutical Preparations

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

AstraZeneca PLC

AZN · Pharmaceutical Preparations

Vanda Pharmaceuticals Inc.

VNDA · Pharmaceutical Preparations

Last updated: 24/09/2026

Jazz Pharmaceuticals plc (JAZZ) Revenue, Earnings & Financials 2025 – Clarifo